AIM-HIGH trial

AIM-HIGH was a multi-center clinical trial related to the prophylactic treatment coronary artery disease involving some 90 sites in the United States and Canada, which was conducted between 2006 and 2012 and involved 3,414 volunteers [1].

AIM-HIGH was an acronym for Atherothrombosis Intervention in Metabolic Syndrome with low HDL/HIGH Triglycerides trial[2]

Description

The trial was designed to test whether adding high dose, extended-release niacin to simvastatin may be a better than statin therapy alone in reducing long-term cardiovascular events. The participants, who all had a history of cardiovascular disease, were selected according to the following profile: [3]

Results

The trial was stopped early because there was a demonstrable lack of efficacy for this intervention. The addition of high dose, extended release niacin to a statin did increase HDL cholesterol, as expected, but did not reduce cardiovascular events. The analysis also showed that there was little to no probability that adding high-dose, extended release niacin to statin treatment would show a benefit even if the study continued to its originally planned completion.

gollark: (it serves HTTP, connects to an MPD instance, connects to an IRC server, and serves DNS, simultaneously)
gollark: And probably just add it to my horribly convoluted python server thing.
gollark: Well, I would avoid PHP at all costs.
gollark: JS fits this (if you like brackets), but is terrible in other ways.
gollark: Tons of esolangs.

References
  1. National Heart Lung & Blood Institute (USA) Questions and Answers: AIM-HIGH Study, May 26, 2011
  2. Healio Cardiology Review of AIM-HIGH trial
  3. New England Journal of Medicine 2018-09-17 pp 2255 - 2267


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.